RUOLO DEL CABAZITAXEL NEL TRATTAMENTO DEL PAZIENTE ANZIANO CON CARCINOMA PROSTATICO RESISTENTE ALLA CASTRAZIONE
H. Lipari, S. G. Rametta, S. Bordonaro, A. Di Mari, E. Lantieri, F. Romano, P. Tralongo
Vol.2 (2017), issue 1, pag. 1-12

Received 06/02/2017
Accepted for pubblication 07/04/2017
Published Apr. 2017
Review by Single-blind
jQuery UI Dialog - Animation

Prostate cancer is the most common malignant neoplasm in the elderly and its incidence in western countries is steadily increasing. Over the past 10 years we have seen the emergence of numerous studies that have allowed the indication of many drugs in the metastatic setting castration resistant (mCRPC). Studies on the evolution of prostate cancer have demonstrated the central role of chemotherapy at different stages of metastatic disease, even in patients resistant or progressed after previous treatment with Docetaxel. Chemotherapy must therefore also have proposed in elderly patients regardless of chronological age, but mainly considering its functional status and the real aims of the treatment. Cabazitaxel in patients with mCRPC progressing after a previous docetaxel chemotherapy, has proven to be effective and well tolerated in older patients. Clinical experience and the different studies in Real Life have in fact given rise to the good drug tolerability in patients aged> 75 years. In this review, we shown the data regarding the chemotherapy treatment with Cabazitaxel in the elderly and suggest it use in clinical practice.